Table 1.
Selected NRAS-mutant melanoma clinical trials.
| Study | Phase | N | Arms | ORR (%) | DCR (%) | PFS (mo) | OS (mo) |
|---|---|---|---|---|---|---|---|
| Dummer et al. 2017 [18] | 3 a,e | 402 | Binimetinib; Dacarbazine | 15; 7 | 58; 25 | 2.8; 1.5 | 11; 10.1 |
| Lebbe et al. 2016 [19] | 2 b,e | 194 | Pimasertib; Dacarbazine | 27; 14 | 33; 16 | 3.3; 1.7 | 8.9; 10.6 |
| Ascierto et al. 2013 [20] | 2 d | 30 | Binimetinib | 10 | 63 | 3.7 | NS |
| Kirkwood et al. 2012 [21] | 2 c,e | 10; 18 | Selumetinib; Temozolomide | 0; 6 | 50; 55 | NS | NS |
| Kim et al. 2019 [22] | 1 e | 9 | Belvarafenib | 44 | NS | 6.2 | NS |
| Schuller et al. 2017 [23] | 1b e | 16 | Ribociclib + Binimetinib | 25 | 69 | 6.7 | NS |
| Algazi et al. 2017 [24] | 1 d,e | 10 | GSK2141795 f + Trametinib | 0 | 40 | 2.3 | 4 |
| Sullivan et al. 2017 [25] | 1 e | 18 | Ulixertinib | 17 | NS | NS | NS |
| Falchook et al. 2012 [26] | 1 b,e | 7 | Trametinib | 0 | 22 | NS | NS |
Abbreviations: ORR, overall response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; NS, not specified. a Analysis of patients with cutaneous melanoma or melanoma with an unknown primary; b analysis of patients with cutaneous melanoma; c analysis of patients with cutaneous and mucosal melanoma or melanoma with an unknown primary; d analysis of patients with cutaneous and mucosal melanoma.; e results shown only for patients with NRAS mutations; f AKT inhibitor.